KSKarin Steinke

Karin Steinke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karin Steinke has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long‐term outcome following microwave ablation of early‐stage non‐small cell lung cancer

    by Henry Zhao, Karin Steinke

    Introduction: This study aimed to evaluate the long‐term outcome of microwave ablation (MWA) of early‐stage non‐small cell lung cancer (NSCLC), including response to treatment and survival.Methods: This retrospective study was conducted on consecutive patients who underwent computed tomography‐guided MWA of early‐stage NSCLC (no evidence of nodal or distant metastasis) from November 2010 to December 2014 at our institution. Data were collected from systematic review of patient charts and imaging. Procedural complications, response to treatment and survival were assessed.Results: 34 early‐stage (T1a‐T3N0M0) NSCLCs in 30 patients were treated with a total of 41 MWA sessions. There were no intraprocedural or 30‐day post‐procedural deaths. The most common complication was pneumothorax, encountered in 24 (59%) microwave ablation sessions, six (15%) of which required chest tube insertion. Over a median computed tomography follow‐up period of 39 months (range 3–89), 24 (71%) NSCLCs demonstrated local control, while 10 (29%) demonstrated local progression. Nodal/distant progression was more common than local progression, with 15 of the 30 patients (50%) having nodal or distant metastases at follow‐up. Patient survival status was followed up over a median period of 56.5 months (range 10–107). Median overall survival and 5‐year overall survival were 56.5 months (95% confidence interval, 26‐not reached) and 46.7% (95% confidence interval, 31.8–68.4), respectively.Conclusion: MWA is safe and effective at achieving local control of early‐stage NSCLC and may prolong patient survival. Nodal or distant metastases were the dominant manifestations of disease progression at long‐term follow‐up.


  • Delayed complications following microwave ablation of lung tumours

    by James Harvey, Morgan N Windsor, Karin Steinke

    Summary: The majority of complications following microwave ablation (MWA) of lung tumours are immediately evident, however, delayed complications do occasionally occur. The radiologist plays a major role in identifying and in guiding the management of these complications. This pictorial essay explores the imaging appejmironce of several potentially life‐threatening delayed complications of pulmonary MWA.


  • Open Access

    Are modified RECIST the gold standard for response assessment of lung tumours treated with microwave ablation?

    by Masaki Bannai, Steven Smith, Satomi Okano, Anita Pelecanos, Karin Steinke

    Introduction: mRECIST were introduced in early 2000 for radiofrequency ablation (RFA) of lung tumours. This retrospective study was performed to evaluate mRECIST in the assessment of lung tumours treated with microwave ablation (MWA). Material and Methods: All percutaneous CT–guided MWA of lung tumours performed between June 2010 and December 2016 were identified and cases with at least 10 months follow-up were included. The therapeutic response was evaluated based on mRECIST. Results: Of the 35 patients included 23 had non-small cell lung cancer (NSCLC) and 12 patients had colorectal cancer (CRC) metastases. Compared to the 24-h post-ablation scan, at 24 months the median CT mass size had reduced to 51.1% from baseline. Based on mRECIST, at 12 months 84.8% showed partial response and 15.2% had stable disease. At 24 months 90% (n = 20) showed partial response whereas 5% had stable disease and another 5% showed complete response. A large proportion of patients were alive 12 months after MWA with a partial response based on mRECIST; this partial response rate had not changed at the 24 months mark. Conclusion: This study challenges the use of mRECIST for the assessment of therapeutic response of lung tumours treated with MWA suggesting that timelines, especially regarding the baseline scan and ablation characteristics, may need to be revised.

  • Open Access

    Repeat thermal ablation for local progression of lung tumours: how safe and efficacious is it?

    by Henry Zhao, Satomi Okano, Anita Pelecanos, Karin Steinke

    Keywords: Local progression, lung tumours, microwave ablation, radiofrequency ablation, repeat ablation


  • Open Access

    The wanderlust of a gallstone: a case report of intrathoracic migration of a gallstone post complicated cholecystectomy mimicking lung cancer

    by Alya Saeed Binmahfouz, Karin Steinke

    Gallstones migrating into the right hemithorax post complicated cholecystectomy may be misdiagnosed for lung cancer, especially in the context of a distant history of cholecystectomy, poor historians and incomplete patient data. We present a case of a female patient with heavy smoking history who presented to our emergency department with haemoptysis and mild weight loss. Imaging workup showed an FDG-PET positive heterogeneous nodule with central calcification in the right lower lobe, carrying lung cancer as a differential diagnosis. The resected specimen revealed an inflammatory pseudomass formed around a gallstone. This case illustrates the importance of knowing the spectrum of clinical and radiological presentation of a gallstone migrating into the right hemithorax, in order to prompt appropriate management and prevent misdiagnosis and mistreatment.


  • Percutaneous CT-guided thermal ablation as salvage therapy for recurrent non-small cell lung cancer after external beam radiotherapy: A retrospective study

    by Matthew Cheng, Michael Fay, Karin Steinke

    Purpose: The aim of this study was to evaluate radiofrequency ablation (RFA) and microwave ablation (MWA) as a viable salvage option for patients with locally recurrent non-small cell lung cancer (NSCLC) after radiotherapy. Materials and methods: This retrospective study was conducted on patients who had received thermal ablation for recurrent NSCLC post-curative radiotherapy. Medical records and follow-up imaging with computed tomography (CT) and PET-CT were analysed to determine time to local progression (TTLP) and overall survival (OS). TTLP was determined according to the modified RECIST criteria. Results: Twelve patients, mean age 71 ± 7 years, received 17 thermal ablation sessions, with RFA performed for four lesions and MWA for 13. Nine tumours were squamous cell cancers (SCC) and eight were adenocarcinomas. Eleven tumours had recurred post-external beam radiation and one post-stereotactic body radiation therapy. Mean tumour size was 34.2 ± 12.8 mm, tumour stages prior to radiotherapy were Ia (2), Ib (3), IIa (4), IIb (1) and III (2). Follow-up period was 19 ± 11 months. Overall median TTLP was 14 months (95% CI: 8, 19), and median OS was 35 months (95% CI: 12, 58). Mean TTLP for tumours 30 mm 14 months (p = 0.20). Recurrence rates reduced from 50% after initial ablation to 20% with a second ablation. Complication rate for pneumothorax requiring intervention was 17%. Conclusion: Both RFA and MWA ablation prolonged local tumour control with minimal morbidity in this study group of recurrent NSCLC after radiotherapy.


  • Would you bet on PET? Evaluation of the significance of positive PET scan results post‐microwave ablation for non‐small cell lung cancer

    by Syed N Zaheer, Justin M Whitley, Paul A Thomas, Karin Steinke

    Fluodeoxyglucose-positron emission tomography (FDG-PET) imaging is an acknowledged modality for the follow-up of solid tumours treated with thermal ablation, with persistent or new FDG uptake at the ablation site considered to be a reliable indicator of local recurrence. Several cases of proven false-positive FDG-PET scans are illustrated in this pictorial essay with uptake at the site of the ablated tumour, remote from the ablated lesion and in mediastinal and hilar lymph nodes. Positive FDG-PET scans post-thermal ablation of lung tumours therefore cannot always reliably predict local tumour recurrence or nodal spread. It is important to be familiar with FDG uptake patterns post-ablation and their significance. FDG-PET avid lesions post-ablation may require histological confirmation before further therapy is planned or management is changed.


  • Percutaneous microwave ablation for early‐stage non‐small cell lung cancer (NSCLC) in the elderly: A promising outlook

    by Christian Acksteiner, Karin Steinke

    Introduction: Microwave ablation (MWA) is a relatively new minimally invasive treatment option for lung cancer with substantially lower morbidity and mortality than surgery. This retrospective study was performed to evaluate the safety, effectiveness and follow‐up imaging of MWA in the elderly aged 75 years and above.Methods: Eleven percutaneous computed tomography (CT)‐guided MWA of early‐stage non‐small cell lung cancer (NSCLC) were performed in 10 patients aged 75 years and older. All but one patient were treated with a high‐powered MWA system delivering maximally 140 W. Follow‐up with CT and fludeoxyglucose‐positron emission tomography (FDG‐PET) was carried out over a maximum period of 30 months and a median period of 12 months.Results: There were no peri‐procedural deaths or major complications. Seven patients were disease free at the time of manuscript submission. Three patients showed growth of the treated lesions, one patient aged 90 years deceased due to unknown cause after approximately 18 months. One patient presented with local progression and disseminated metastatic disease at 12 months; he is still alive. One patient showed increasing soft tissue at the ablation site 15 months post‐treatment. Three consecutive core biopsies over 2 months failed to confirm tumour recurrence.Conclusions: MWA therapy is a promising option of treating early‐stage NSCLC in the elderly with good treatment outcome and negligible morbidity. Determining successful treatment outcome may be challenging at times as local tissue increase and PET‐CT positivity do not seem to necessarily correlate with reccurrence of malignancy.


  • Open Access

    Retrocardiac mass in a patient with cirrhosis: A case report

    by Mehdi Saeidpour, Karin Steinke

    The most common cause of a supradiaphragmatic posterior mediastinal mass is a hiatus hernia. However, an unexplained round or lobulated retrocardiac shadow without air or air-fluid level in patients with marked portal hypertension should raise the suspicion of dilated venous collaterals. This is a case of a 58-year-old Asian male with a history of chronic liver disease secondary to alcohol abuse and hepatitis B and banding of esophageal varices due to bleeding presenting to the hospital after a low-velocity motor vehicle accident. Plain X-ray of chest showed a double density structure through the left cardiac shadow. Further investigation revealed paraesophageal varices simulating a retrocardiac mass on a contrast enhanced helical computed tomography scan of the abdomen. Differential diagnoses of mediastinal, retroperitoneal, and mesenteric masses in patients with cirrhosis most commonly include varices rather than a neoplasm or adenopathy. Portosystemic collateral veins most likely need many years to reach such a size that they can be visible on a chest X-ray. Giant esophageal varices may present as a posterior mediastinal mass on a chest X-ray in as many as 5% of cirrhotic patients. Diagnosis may be confirmed by Doppler ultrasonography, computed tomography scan, or magnetic resonance imaging scan. Correct interpretation of a pseudotumor caused by venous collaterals may avoid potentially hazardous invasive diagnostic procedures.

  • Case report: Positron emission tomography fails to detect pulmonary adenocarcinoma recurrence after radiofrequency ablation

    by Karin Steinke, Cara Odenthal

    We describe the case of late recurrence of a focus of invasive mucinous adenocarcinoma (formerly mucinous bronchioloalveolar carcinoma) following radiofrequency ablation, despite a negative positron emission tomography/computed tomography scan at 13 months following the ablation. A computed tomography scan performed at 24 months demonstrated unequivocal recurrence of the lesion. Combined positron emission tomography/computed tomography has been described as an adequate modality for the follow-up of thermally ablated pulmonary lesions. However, its utility in the follow-up of well-differentiated pulmonary adenocarcinoma may be limited. Lesion activity may be underestimated by an inherently low metabolic activity. Small lesions may also be susceptible to partial volume effect. Long-term imaging follow-up of well-differentiated pulmonary adenocarcinoma beyond two years after thermal ablation is prudent to avoid missing late recurrence.